MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijrobp.2024.07.2333

Медицинская библиотека · International journal of radiation oncology, biology, physics · 2024

Concerning Safety and Efficacy of Concurrent and Consolidative Durvalumab With Thoracic Radiation Therapy in PDL1-Unselected Stage III Non-Small Cell Lung Cancer: Brief Report.

Zhang Yuanyuan, Iyengar Puneeth, Montalvo Steven, Westover Kenneth D, Rashdan Sawsan, Donthireddy Kavitha, Kim James, Dowell Jonathan E, Drapkin Benjamin, Bhalla Sheena, Chukwuma Christian, Nadeem Urooba, Ahn Chul, Timmerman Robert D, Gerber David E

СтатьяКлиническое исследование II фазыПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

PURPOSE: Consolidative durvalumab, an anti-programmed death ligand 1 (PDL1) immune checkpoint inhibitor, administered after concurrent chemoradiation improves outcomes of patients with locally advanced non-small cell lung cancer (NSCLC) without substantially increasing toxicities. We studied a chemotherapy-free regimen of thoracic radiation therapy (RT) with concurrent and consolidative durvalumab.

METHODS AND MATERIALS: This single-arm phase 2 trial enrolled patients with stage III NSCLC (regardless of tumor PDL1 expression), Eastern Cooperative Oncology Group (ECOG) performance status 0-1, adequate pulmonary function, and RT fields meeting standard organ constraints. Participants received 2 cycles of durvalumab (1500 mg every 4 weeks) concurrently with thoracic RT (60 Gy in 30 fractions), followed by up to 13 cycles of consolidative durvalumab.

RESULTS

After 10 patients were enrolled, the trial was closed because of poor clinical outcomes. With a median follow-up of 12 months, 5 patients had disease progression and 8 patients died. Six patients experienced 15 treatment-related, grade ≥3 events, including 1 grade 4 acute kidney injury during consolidation and 2 fatal pulmonary events. One fatal pulmonary event occurred during the concurrent phase in an active smoker; the other occurred after the first cycle of consolidative durvalumab. The primary endpoint of progression-free survival at 12 months was 20% (50% for PDL1≥1% vs 0% for PDL1 unavailable or <1%). Median overall survival was not reached, 10.5 months, and 7 months, for PDL1 ≥1%, <1%, and unavailable, respectively.

CONCLUSIONS

In PDL1 unselected stage III NSCLC, thoracic RT plus concurrent and consolidative durvalumab is associated with high-grade toxicity and early disease progression.

Для цитирования: Zhang Yuanyuan, Iyengar Puneeth, Montalvo Steven, Westover Kenneth D, Rashdan Sawsan, Donthireddy Kavitha, Kim James, Dowell Jonathan E, Drapkin Benjamin, Bhalla Sheena, Chukwuma Christian, Nadeem Urooba, Ahn Chul, Timmerman Robert D, Gerber David E. Concerning Safety and Efficacy of Concurrent and Consolidative Durvalumab With Thoracic Radiation Therapy in PDL1-Unselected Stage III Non-Small Cell Lung Cancer: Brief Report.. International journal of radiation oncology, biology, physics. 2024. DOI: 10.1016/j.ijrobp.2024.07.2333.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.